Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-15
2005-03-15
Saeed, Kamal (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S530000, C558S288000
Reexamination Certificate
active
06867306
ABSTRACT:
The present invention discusses a novel process for the synthesis of [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium, atorvastatin. The compound so prepared is useful as inhibitor of the HMG-CoA reductase and may thus be used as hypolipidemic and hypocholesterolemic agent.
REFERENCES:
patent: 4681893 (1987-07-01), Roth
patent: 5003080 (1991-03-01), Butler et al.
patent: 5084392 (1992-01-01), Miyazawa et al.
patent: 5097045 (1992-03-01), Butler et al.
patent: 5103024 (1992-04-01), Millar et al.
patent: 5124482 (1992-06-01), Butler et al.
patent: 5149837 (1992-09-01), Butler et al.
patent: 5155251 (1992-10-01), Butler et al.
patent: 5216174 (1993-06-01), Butler et al.
patent: 5245047 (1993-09-01), Butler et al.
patent: 5248793 (1993-09-01), Millar et al.
patent: 5273995 (1993-12-01), Roth
patent: 5292939 (1994-03-01), Hollingsworth
patent: 5319110 (1994-06-01), Hollingsworth
patent: 5374773 (1994-12-01), Hollingsworth
patent: 5397792 (1995-03-01), Butler et al.
patent: 6274740 (2001-08-01), Lin et al.
patent: 6528661 (2003-03-01), Niddam et al.
patent: 20020099224 (2002-07-01), Niddam et al.
patent: 20030114685 (2003-06-01), Niddam-Hildesheim et al.
patent: 20030175338 (2003-09-01), Singh et al.
patent: WO 9703958 (1997-02-01), None
patent: WO 9703960 (1997-02-01), None
patent: WO 0053566 (2000-09-01), None
patent: WO 0068221 (2000-11-01), None
patent: WO 0110813 (2001-02-01), None
patent: WO 0128999 (2001-04-01), None
patent: WO 0142209 (2001-06-01), None
patent: WO 0172706 (2001-10-01), None
patent: WO 0243667 (2002-06-01), None
patent: WO 02057228 (2002-07-01), None
patent: WO 03004450 (2003-01-01), None
patent: WO 03004455 (2003-01-01), None
patent: WO 03004456 (2003-01-01), None
patent: WO 03016317 (2003-02-01), None
International Search Report issued for corresponding PCT application PCT/IN01/00114 (WO02/027274 A1).
Akira et al., “A Novel Synthesis of (R)- and (S)-4-Hydroxytetrahydrofuran-2-ones”,Synthesis, 6:570-573, 1987.
Baumann, et al., “The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase”,Tetrahedron Letters, 33(17):2283-2284 (1992).
Saito, et al., “Combination of Borane-Dimethyl Sulfide Complex with Catalytic Sodium Tetrahydroborate as a Selective Reducing Agent for α-Hydroxy Esters, Versatile Chiral Building Block from (S)-(−)-Malic Acid,”,Chemistry Letters, 1389-1392 (1984).
Shieh et al., “Stereoselective Alkylation and Aldol Reactions of (S)-(−)-β-Hydroxy-γ-butyrolactone Dianion”,J. Org. Chem., 46:4319-4321 (1981).
Graul et al., “Atorvastatin calcium”, Drugs of the future (1997), 22(9), 956-968.
Lee et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part II. Synthesis of side chain-labeled [14C] atorvastatin”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 129-133.
Manzoni et al., “Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs”, Applied Microbiology and Biotechnology (2002), 58(5), 555-564.
Oehrlein R et al., “Chemoenzymatic approach to statin side-chain building blocks” Advanced Synthesis Catalysis (2003), 345 (6+7), 713-715.
Radl et al., “An Improved synthesis of 1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for atorvastatin synthesis”, Tetrahedron Letters (2002), 43(11), 2087-2090.
Roth, Bruce D., “The discovery and development of atorvastatin, a potent novel hypolipidemic agent”, Progress in Medicinal Chemistry (2002), 40, 1-22.
Wierzbicki, Anthony S., “Atorvastatin”, Expert Opinion on Pharmacotherapy (2001), 2(5), 819-830.
Woo et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part I. Synthesis of ring-labeled [14C] atorvastatin”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 121-127.
Woo et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part III. Synthesis of [2H5]-, [13C8], and [13C7, 15N] atorvastatin and their application in metabolic and pharmacokinetic studies”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 135-145.
Mathew Joy
Sambasivam Ganesh
Sridharan Madhavan
Srinath Sumitra
Ujire Sandhya
Biocon Limited
Choate Hall & Stewart
Lagneau Nadege
Pasternack Sam
Saeed Kamal
LandOfFree
Process for the synthesis of atorvastatin form v and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the synthesis of atorvastatin form v and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the synthesis of atorvastatin form v and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3406042